Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers M > Headlines for MannKind Corp. > News item |
MannKind still neutral by Merrill
Merrill Lynch analyst Hari Sambasivam kept MannKind Corp. at neutral after third-quarter results were in line with estimates. Total expenses were $61.1 million, including R&D of $50.8 million and SG&A of $10.3 million against estimates of $58.0 million, $47.5 million and $10.5 million. Shares of the Valencia, Calif.-based biopharmaceutical company were down 7 cents, or 0.41%, at $17.11. (Nasdaq: MNKD)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.